Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)

NCT02720068 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

481

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

BIOLOGICAL: Favezelimab
BIOLOGICAL: Pembrolizumab
DRUG: Oxaliplatin
DRUG: Irinotecan
DRUG: Leucovorin (Calcium Folinate)
DRUG: Fluorouracil [5-FU]
BIOLOGICAL: Favezelimab/Pembrolizumab
DRUG: Lenvatinib

Sponsor

Merck Sharp & Dohme LLC